BioSpace News Archive

Revive Therapeutics Explores the Use of Bucillamine for Long COVID

Revive Therapeutics Ltd. announced today its initiative in Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID.

February 1, 2024

·

4 min read

Business

Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors

Graviton Bioscience along with other therapeutic compounds, announces a strategic investment from Sanofi.

February 1, 2024

·

3 min read

Genetown

Data Demonstrating vMap’s Impact on Atrial Fibrillation Treatment Outcomes Unveiled at AF Symposium 2024

Vektor Medical, a pioneer in non-invasive arrhythmia analysis technology, will release findings today at AF Symposium from the recent study Ablation of Non-Pulmonary Vein Atrial Fibrillation Drivers Identified by Machine Learning in Addition to Pulmonary Vein Isolation Improves Procedural Outcomes.

February 1, 2024

·

3 min read

Drug Development

RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung

RS Oncology today announced the successful dosing of the first patient in the Phase 2 dose expansion portion of its United Kingdom multicenter study (MITOPE; NCT05278975 ).

February 1, 2024

·

3 min read

Corporate Update on Clinical Evaluation of MedMira’s Products

MedMira Inc. is pleased to provide an update on the ongoing review process by Health Canada.

February 1, 2024

·

3 min read

Business

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024

Organon will release its fourth quarter and full year 2023 financial results on February 15, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.

February 1, 2024

·

2 min read

Drug Development

EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis

EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2) evaluating Focal One High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of deep infiltrating rectal endometriosis.

February 1, 2024

·

6 min read

Genetown

Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference

Mersana Therapeutics, Inc. today announced that members of management will participate in a fireside chat at Guggenheim’s 6th Annual Biotechnology Conference on February 8, 2024 at 11:30 a.m. ET.

February 1, 2024

·

1 min read

Pharm Country

Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Tourmaline Bio, Inc. today announced that Sandeep Kulkarni, CEO, will present at the in the following investor conference.

February 1, 2024

·

1 min read

Pharm Country

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON TrialAccepted for Presentation at the 2024 International Stroke Conference

Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company) today announced that a poster outlining its pivotal Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405) has been accepted for presentation at the 2024 International Stroke Conference, to be held February 7-9, 2024 in Phoenix, AZ.

February 1, 2024

·

6 min read